Phase 1 Systemic Lupus Erythematosus, SLE trials recruiting now

All Systemic Lupus Erythematosus, SLE trials, every phase

Other phases for Systemic Lupus Erythematosus, SLE

Phase 1 Systemic Lupus Erythematosus, SLE trials

• A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
  NCT07444307 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
  NCT07413341 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
  NCT07104721 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
  NCT06978647 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
  NCT07123519 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
  NCT06308978 · Phase: Phase 1 · Ages: 12 Years to 70 Years · Sex: All (male and female) · 21 locations
• A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
  NCT06249438 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
  NCT07331272 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 5 locations
• A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
  NCT06980597 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
  NCT06647069 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
  NCT06585514 · Phase: Phase 1, Phase 2 · Ages: 3 Years to 65 Years · Sex: All (male and female) · 1 location
• Blinatumomab in Refractory Active Childhood Systemic Lupus Erythematosus
  NCT06789107 · Phase: Phase 1 · Ages: 5 Years and older · Sex: All (male and female) · 2 locations
• CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
  NCT06839976 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 29 Years · Sex: All (male and female) · 1 location
• CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
  NCT06822881 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Clinical Study of Cizutamig in Systemic Lupus Erythematosus
  NCT07215663 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 17 locations
• Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
  NCT06892145 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
  NCT06032923 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 120 Years · Sex: Female · 1 location
• Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
  NCT07236801 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• FT839 in Autoimmune Diseases
  NCT07800871 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
  NCT06675422 · Phase: Phase 1, Phase 2 · Ages: 14 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
  NCT07085676 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 2 locations
• Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
  NCT07031713 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
  NCT07010835 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
  NCT07185269 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells
  NCT07041801 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
  NCT06737380 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.